Priority 21 from the Mesothelioma PSP
|UNCERTAINTY: What is the current best method (e.g. contrast enhanced MRI vs PET) to accurately assess disease progression in mesothelioma patients? (JLA PSP Priority 21)
|JLA question ID
|Not available for this PSP
|No systematic reviews or studies identified
|Health Research Classification System category
|Extra information provided by this PSP
|Original uncertainty examples
|How do you accurately assess disease progression?
|Outcomes to be measured
|Detection of progression
|PSP unique ID
|Total number of uncertainties identified by this PSP.
|53 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
|Date of priority setting workshop
|16 December 2014